Sphingolipids regulate cellular processes that are critically important in cell's fate and function in cancer development and progression. This fact underlies the basics of the novel cancer therapy approach. The pharmacological manipulation of the sphingolipid metabolism in cancer therapeutics necessitates the detailed understanding of the pathway. Two computational systems biology tools are used to identify potential drug target enzymes among sphingolipid pathway that can be further utilized in drug design studies for cancer therapy. The enzymes in sphingolipid pathway were ranked according to their roles in controlling the metabolic network by metabolic control analysis. The physiologically connected reactions, i.e. biologically significant and functional modules of network, were identified by metabolic pathway analysis. The final set of candidate drug target enzymes are selected such that their manipulation leads to ceramide accumulation and long chain base phosphates depletion. The mathematical tools' efficiency for drug target identification performed in this study is validated by clinically available drugs.
Introduction
Sphingolipids comprise a class of complex lipids which are abundantly found in cell membrane. These membrane lipids do not only function as structural components of the cell membrane but they possess important roles in signal transduction (as second messengers) and in regulatory pathways such as cell cycle arrest, apoptosis, senescence and differentiation. The investigation of the processes that are regulated by bioactive sphingolipid signaling molecules demonstrates that sphingolipids are fundamental to cancer pathogenesis and therapeutics [1] . Ceramide, an essential building block of sphingolipids, has been suggested to be a reasonable key metabolite in cancer therapy inducing antiproliferative and apoptotic responses. Many anti-cancer drugs are reported to lead to increased endogenous ceramide levels. Ceramide's influence on cell growth is dynamically balanced by sphingosine-1-phosphate and this balance is termed as ''sphingolipid rheostat". In cancer cells, this dynamic balance is missing [1] [2] [3] [4] [5] [6] [7] [8] .
A novel cancer therapy approach resides on the adjustment of the sphingolipid metabolism to accumulate ceramide and to decrease sphingosine-1-phosphate based on the fact of ceramide being a ''tumor-suppressor lipid" and sphingosine-1-phosphate being a ''tumor-promoting lipid". The drugs using this fact are expected to resemble the antiproliferative and apoptotic responses in the cell by altering the sphingolipid levels. The advantages of such changes are not only in cancer therapy but also, enhancement of drug action and chemoprevention [1, [6] [7] [8] .
There are several newly developed synthetic inhibitors of specific enzymes involved in sphingolipid metabolism [9] . The target enzymes of human sphingolipid pathway are serine palmitoyl transferase, ceramide synthase, ceramidase, sphingosine kinase, glucosylceramide synthase, 1-O-acylceramide synthase. A number of drugs like N-4-hydroxyphenyl retinamide (4-HPR), Valspodar (PSC 833), daunorubicin, ceramide analog (B13), safingol, butyldeoxynojirimycin and phenoxodiol targeting the above listed enzymes are in pre-clinical or clinical development [7, [9] [10] [11] [12] . Changing ceramide levels in favor of cancer therapy seems to be a promising strategy if the developed drugs targeting the newly identified sphingolipid enzymes are selective toward malignant cells but not healthy cells. With some ceramidase inhibitor trials this selectivity seems to be possible due to the hypersensitivity of malignant cells to ceramide perturbation [7] . Another evidence for the significance of accumulation of ceramide in cancer cells is that cancer cells escape from apoptosis by degrading, catabolizing or converting ceramide [9] . Experimentalists observed elevated levels of acid ceramidase expression in human prostate cancer cell lines [13] . The manipulation of these cellular processes gives the chance of developing new anti-cancer therapeutics and indeed, forms the basics of the novel cancer therapy method [1] .
The most difficult step in drug discovery is the decision of the drug target enzymes. Since clinical aspects of sphingolipids are still lacking information, the identification of drug targets by employing computational tools is a significant requirement. Metabolic control analysis is a powerful mathematical tool to solve this puzzle of drug target identification via considering the role of individual components within a metabolic network [14] . As mentioned previously, sphingolipids regulate processes that are vital in terms of cell's fate. These processes are all very important for cancer initiation, progression and treatment [6] . The identification of critical enzymes within sphingolipid metabolism facilitates the link between sphingolipids and cancer.
In the present study, the key points of sphingolipid metabolism in terms of ceramide and sphingosine-1-phosphate are investigated using two different mathematical frameworks, metabolic control analysis and metabolic pathway analysis. Metabolic control analysis is based on dynamic data whereas metabolic pathway analysis uses the stoichiometry of the system. These two systems biology tools reveal the important metabolic steps of the sphingolipid pathway and using this information novel drug target enzymes can be recognized and potential drug target enzymes in human pathway can be proposed. Although the Saccharomyces cerevisiae and human sphingolipid pathways are similar to each other, one should admit that S. cerevisiae sphingolipid pathway consists of only few complex sphingolipids when compared with that of mammalian cells/human. Thus, this study can be considered as an attempt to bridge the basic sphingolipid research to potential medical applications in cancer therapy.
Computational methods
In order to gain a better understanding of sphingolipid metabolism, S. cerevisiae is taken as the model system. The availability of the detailed and complete enzymatic and genetic data of S. cerevisiae makes the organism eligible for computational works that can give reliable first guesses for human studies. The conservation of sphingolipid metabolic and regulatory pathways across species has been used in the identification of the corresponding mammalian orthologues [15] [16] [17] [18] . In the present study, the protein sequence homologies of the enzymes that are responsible for the sphingolipid pathway activity were cross-checked against human (Homo sapiens) proteome via NCBI (National Center for Biotechnology Information) protein blast utility. Almost all the enzymes involved in the sphingolipid reactions of the model system have a homolog in human proteome with a reasonable and exceptable E-value, which shows the similarity of the two protein sequences. Also the functional domains of the yeast and human sphingolipid homolog proteins were compared and almost complete overlap is observed. The de novo sphingolipid metabolism of yeast exactly matches to that of human with the exception of the double bonded ceramide in human which is missed in yeast cells. The complex sphingolipids of yeast and human differ but the potential drug targets proposed in the current study correspond to mainly de novo sphingolipid synthesis.
Sphingolipid metabolic pathway
This model system consists of three parts. The main part is the sphingolipid metabolism and the two auxiliary pathways are the fatty acid metabolism and phospholipid metabolism. They integrate sphingolipid metabolism to other cellular processes. The fatty acid metabolism reactions used in the model system are steps that correspond to the synthesis and elongation of fatty acids. The very long chain fatty acids (C 26 -CoA) are employed as precursors in the synthesis of dihydroceramide (DHCer) and phytoceramide (PHCer). Phospholipid metabolism is also another important branch point at the initial step of sphingolipid, i.e. at palmitoylcoenzyme A (Pal-CoA) level. Synthesis of phosphatidyl inositol (PI) is included in the model system due to the fact that; PI is a precursor metabolite for the synthesis of complex sphingolipid, inositol phosphorylceramide (IPC) from both dihydroceramide and phytoceramide.
The sphingolipid metabolic pathway (Table 1) for the dynamic model is taken from Alvarez-Vasquez et al. [19] and explained below. The first reaction of the de novo sphingolipid synthesis is the condensation of serine and Pal-CoA via the enzyme serine palmitoyl transferase, r 11 , and takes place in the endoplasmic reticulum. This reaction produces the precursor metabolite 3-ketodihydrosphingosine (KDHS) which is required for the synthesis of the first long chain base, dihydrosphingosine (DHS). KDHS is rapidly reduced to the long chain base, r 13 , catalyzed by 3-ketodihydrosphingosine reductase in the endoplasmic reticulum. The condensation reaction can be named as the initializing step of de novo sphingolipid synthesis in S. cerevisiae [2, 16, 17] .
After the formation of the sphingoid long chain bases in S. cerevisiae, there are two alternative paths that the long chain bases can follow: acylation or phosphorylation. Dihydrosphingosine (DHS) and phytosphingosine (PHS) are acylated to DHCer, r 23 , and PHCer, r 24 , respectively, by ceramide synthase and the reactions take place in endoplasmic reticulum [16, 19, 20] . The enzyme responsible for the phosphorylation of the long chain bases to long chain base phosphates is sphingoid base kinase which catalyzes the synthesis of dihydrosphingosine-1-phosphate (DHS-P) and phytosphingosine-1-phosphate (PHS-P), r 15 and r 20 , respectively. The reverse reactions, dephosphorylations, r 14 and r 19, are also possible by the enzyme sphingoid-1-phosphate phosphatase in endoplasmic reticulum of S. cerevisiae . The phosphorylation and dephosphorylation steps are needed for the synthesis of sphingolipids. The phosphorylated long chain bases can be decomposed by the enzyme sphingosine-phosphate lyase to cytidine diphosphate-ethanolamine (CDP-E), r 17 and r 18 . At this point sphingolipid pathway is again linked to the phospholipid pathway [16, 19] .
DHCer and PHCer can be converted back to long chain bases of DHS and PHS, r 22 and r 25 , by dihydroceramide and phytoceramide alkaline ceramidases in the endoplasmic reticulum [16, 19] . Hydroxylation of DHS and DHCer to PHS, r 21 , and PHCer, r 26 , respectively, are catalyzed by sphingosine hydroxylase encoded by SUR2 in endoplasmic reticulum [20] . This enzyme is responsible for the adjustment of balance between the two S. cerevisiae sphingoid long chain bases [16, 19] . This step does not take place in mammalian cells, where dihydroceramide is desaturated to form ceramide but not phytoceramide [1] .
In S. cerevisiae three types of complex sphingolipids containing myo-inositol are synthesized: inositol phosphorylceramide (IPC), r 29 and r 30 , mannosylinositol phosphorylceramide (MIPC), r 39 , and mannosyldiinositol phosphorylceramide (M(IP) 2 C), r 49 . As the only alteration of ceramide in S. cerevisiae is by the addition of inositol phosphate (IP), these three complex sphingolipids are the end products of S. cerevisiae sphingolipid metabolism. This modification by IP occurs only in S. cerevisiae but not in mammalian cells; therefore IPC, MIPC, M(IP) 2 C may not be found in mammalian cells. In S. cerevisiae, complex sphingolipid synthesis reactions are reported to occur in the Golgi apparatus [2, 16] .
There are 49 irreversible reactions in S. cerevisiae sphingolipid metabolism. The enzymes corresponding to each reaction are listed in Table 1 . Thirty-one metabolites with their abbreviations are given in Table 2 . The rate equations are taken from Alvarez-Vasquez et al. [19] who used Biochemical Systems Theory (BST) and Generalized Mass Action (GMA) representation. The rate expressions for each reaction represent the effect of the substrate concentration, the enzyme activity and the modifier concentration [19] . An example for the rate expression of a hypothetical reaction is given by the following equation:
where v is rate, c A is concentration of metabolite A, c B is concentration of metabolite B, c M is concentration of modifier M, X is enzyme activity, and p is kinetic order.
Metabolic control analysis (MCA)
Metabolic control analysis [21] [22] [23] is classified as a post-genomic tool to understand the principles governing a metabolic network's control which is distributed among various enzymatic steps. In this study, metabolic control analysis was employed to quantify the biochemical control of the enzymes constituting the sphingolipid metabolism on the sphingolipid fluxes and concentrations, and hence to determine the candidate enzymes in the metabolic network appropriate as drug targets for antiproliferative and apoptotic responses.
Control coefficients quantitatively describe the relative change in the systematic parameter such as the reaction flux or metabolite concentration with respect to the enzyme activity. When the amount of change in the enzyme activity is same as the change in the systematic property then the control coefficient is unity. A high control coefficient indicates that the change in the enzyme activity is completely reflected to systematic parameter under investigation. The same rationale applies for a low control coefficient such that the change in the enzyme activity has negligible effect on the systematic parameter [14] .The flux control coefficient (C [24] . The concentration control coefficients can take both positive and negative values; a negative control coefficient indicates a negative control effect on the concentration of the metabolite of interest.
As there are various important metabolites/fluxes that have to be considered, three different algorithms were developed to apply a selection criterion for the control coefficients and to identify the vital steps of the pathway (Fig. 1 ). The set of key metabolites consists of DHS, PHS, DHCer, PHCer, DHS-P, PHS-P and all complex sphingolipids at the site of production and plasma membrane (pm) (IPC, IPCpm, MIPC, MIPCpm, M(IP) 2 C, M(IP) 2 Cpm) (indicated as bold in Table 2 ).
Selection criteria
(1) In the first algorithm a global threshold value of 0.4 is chosen for the concentration control coefficients and a matrix that consists of +1, 0 and À1 is constructed. The columns of this matrix contain the set of selected metabolites and the rows contain the enzymatic steps. As there are 49 enzymatic steps and 12 metabolites of interest, the above described binary criterion matrix had the dimensions of 49 Â 12. Absolute j þ 1= À 1j values were used to represent the concentration control coefficients of the metabolites and reactions which are absolutely greater than the global threshold value of 0.4. Thus, this first algorithm does not discriminate between the negative and positive control coefficients. Then the number of non-zero elements in each row was counted and recorded. The enzymes for each reaction step were ranked according to this score representing the reactions that are important for most of the metabolites constituting the set. The enzymes (reactions) that affect at least 50% and more of the 12 critical metabolites with concentration control coefficients higher than 0.4 were selected as the significant enzymes and included in the set of potential drug targets.
The same procedure was applied to the analysis of flux control coefficients. A set of critical reactions were chosen among the ones that are producing and consuming the 12 important metabolites in the previous step of the algorithm. These are the reactions numbered 13-15, 17-31, 38-49 and indicated as bold in Table 1 . The binary criterion matrix had the dimensions of 49 Â 30 where the columns corresponded to the selected reactions instead of the metabolites. In the final step of determining the potential drug target enzymes, the enzymes (reactions) that manipulate at least 50% and more of the 30 important reactions with flux control coefficients higher than 0.4 were selected (Fig. 1) .
(2) In the second algorithm instead of using a global threshold value for both concentration and flux control coefficients, local threshold values are used for each control coefficient examination. The decision of the boundaries, i.e. the local threshold values, is made individually according to the gaps between the coefficients, i.e. the highest differences between the coefficients were taken as break points. After the determination of the threshold values for each control coefficient, the algorithm follows as the previous one (Fig. 1) .
(3) The basic principle underlying in both algorithms was the utilization of the threshold values and the enzymes over a Fig. 1 . The schematic representation of three selection algorithms utilized in the analysis and filtration of metabolic control analysis results. First two algorithms are shown in the same flowchart representation whereas third algorithm is depicted in a separate flowchart. specified threshold are treated equally. In order to use the information embedded in control coefficients more efficiently, a third algorithm is designed where a matrix of concentration control coefficients of the selected critical metabolites is constructed and the maximum values of the absolute control coefficients in each column is found separately. Then concentration control coefficients are normalized with respect to the absolute maximum value of each column so that the matrix at this stage consists of the relative weights of the concentration control coefficients. This stage is a branch point of the algorithm where further analysis involves two approaches, i.e. (i) overall interpretation by average relative weights and (ii) apoptosis specific analysis by relative weights.
First an overall interpretation of the weighted concentration control coefficients are performed which involves averaging the weights for each enzymatic step without considering the direction of action, i.e. signs of the control coefficients. The important reactions from average weights of both concentration control coefficients and flux control coefficients are selected by using a threshold value of 0.5.
Second, in apoptosis specific analysis, the constructed critical metabolite set is partitioned into two parts according to the knowledge about the action of metabolites on apoptosis in mammalian cells. As mentioned formerly, ceramide induces apoptosis whereas sphingosine-1-phosphate promotes cell growth and proliferation. Hence, the concentration control coefficients of DHCer and PHCer are examined separately, and the phosphorylated forms of long chain bases are analyzed accordingly (Fig. 1) .
Metabolic control analysis was performed using the software GEPASI version 3.30 [25] . The ordinary differential equations employed in the metabolic control analysis were also solved under Matlab R2007a using the stiff differential equation solver with the variable order method.
Metabolic pathway analysis (MPA)
Metabolic pathway analysis is a powerful stoichiometric modeling approach for systems biology and used here in the identification of physiologically significant sets of connected reactions in sphingolipid metabolic network. In order to study the inherent network properties, the metabolic reaction network of AlvarezVasquez et al. [19] is reconstructed; the reactions are balanced stoichiometrically using Expasy, KEGG, Brenda databases [29] [30] [31] and the genome scale models from the literature [26] [27] [28] ; and the lumped reactions are decomposed as shown in Fig. 2. 
Improvements in reaction system
The lumped reaction for the synthesis of C 26 -CoA from malonyl-coenzyme A (Mal-CoA) is represented by two distinct reactions: First Mal-CoA is converted to hexacosanoate (Hexco), r 37 , and then converted to C 26 -CoA, r 0 37 , and Pal-CoA is no more a substrate for this reaction. The reaction 36 is modified so that in the newly reconstructed network, palmitate is synthesized by r 0 36 , instead of Pal-CoA. The reaction 6 is also decomposed to two separate reactions, first glucose-6-phosphate (G6P) is converted to inositol-1-phosphate (I1P), r 6 , and then it is converted to inositol, r 0 6 . The products of the decomposition reactions of the phosphorylated long chain bases show also differences with the ones in Alvarez-Vasquez et al.'s pathway [19] . DHS-P and PHS-P are decomposed to ethanolamine phosphate (EP) and palmitaldehyde (PalmA), r 17 and EP and 2-hydroxy-hexadecanal (HPalmA), r 18 , respectively, in the newly reconstructed network. The synthesized EP from these decomposition reactions is converted to cytidine diphosphate-ethanolamine (CDP-E) in Fig. 2 (r 33 ). The products of 17th and 18th reactions catalyzed by lyases were Pal-CoA and CDP-E for both long chain base phosphates in the Fig. 2 . The reaction system used in metabolic pathway analysis. In order to study the inherent network properties, the metabolic reaction network of Alvarez-Vasquez et al. [19] given in Table 1 , is reconstructed; the reactions are balanced stoichiometrically and the lumped reactions are decomposed. The metabolites involved in fatty acid metabolism are shown in octagon boxes; the metabolites of the phospholipids pathway are in oval boxes, and the sphingolipids are shown in rectangular boxes. The dashed boxes show the metabolites that do not fit the above classifications.
older version of the metabolic network. But such distinct reactions are not available in the literature and also when the elements' balance is controlled for the products, it is impossible to balance the elements. A new reaction is added to the metabolic network such that the conversion of PalmA (the decomposition reactions' product) to palmitate, r 50 , and then to Pal-CoA becomes possible, r 1 .
The complex sphingolipids synthesized from DHCer and PHCer are marked as follows: IPC produced from PHCer is named as IPC-PH and represented as IPC-DH if it is synthesized from DHCer. The difference of reactions 38, 39, 41, 45, 46, 47, 48 and 49 from their primed versions are their source, i.e. whether they are produced from DHCer or PHCer. This distinction is made to follow the two types of long chain bases, DHS and PHS (Table 3 ).
Elementary flux modes
Metabolic pathway analysis algorithm involves the calculation of elementary flux modes of the sphingolipid system. Elementary flux modes (EFM) of a metabolic system specify all the possible sets of enzymes that can operate without disturbing the valid steady state of the system [32] [33] [34] [35] [36] . These identified functional pathways cannot be decomposed into smaller meaningful parts and they can be used as the linear basis for the expression of the whole network states. The basic principles that should be satisfied during computation of elementary flux modes are (i) a pseudo steady state condition, (ii) a feasibility condition and (iii) a non-decomposability condition.
First, elementary flux modes were determined using CellNetAnalyzer Version 6.3. [37] , and then a set of key metabolites was Table 3 The balanced reaction list with the enzymes catalyzing the reactions used in metabolic pathway analysis. constructed including DHCer, PHCer, DHS-P and PHS-P due to the significance of ceramide and sphingosine-1-phosphate in apoptosis. The elementary flux modes in that all these key metabolites participate are selected. The reactions that are common in all the selected elementary flux modes are identified and the enzymes catalyzing these common reactions are noted as candidate potential drug targets. The selection of the EFMs that all the elements of the key set participate in and the common reactions occurring in these EFMs is performed by an algorithm coded in MATLAB R2007a.
Control effective flux analysis
The control effective flux (CEF) of a reaction represents the weighted sum of all the fluxes of that reaction observed in all the possible routes (elementary flux modes). So it can be considered as the quantifier of importance of a reaction at steady states. In literature, the control effective flux values were used in the identification of enzymes that can serve as potential drug targets [34, 38] .
The CEF calculation necessitates the definition of substrate uptake reaction and objective reactions. The substrate uptake reaction is chosen to be the 11th reaction catalyzed by Serine Palmitoyl Transferase, since it is the pioneering reaction of the de novo sphingolipid synthesis. In fact the substrates to the sphingolipid metabolism could have been selected as serine and Pal-CoA, but as we could not discriminate between the two in terms of importance, the next step that is the initial step of de novo synthesis is selected as the substrate uptake reaction. The objective reaction issue is resolved by taking into account the key metabolite set employed previously in elementary flux mode analysis. The reactions synthesizing DHCer and PHCer are selected (r 23 and r 24 ) as objective reactions. They serve the aim of accumulation of ceramide in cancer therapy via the manipulation of the sphingolipid pathway. Another facet of the same cancer therapy approach is the depletion of DHS-P and PHS-P, this fact is represented in the objective reaction set by including reactions 17 and 18. Therefore, the first objective function set consists of reactions 17, 18, 23 and 24. The second set additionally contains reactions 14 and 19, converting DHS-P and PHS-P back to the long chain bases. However, the two objective reaction sets make no difference in terms of the consequences so one of them will be discussed in the following sections.
Results
Ceramide and sphingosine-1-phosphate, being the sphingolipid rheostat, are known to play critical roles in cell proliferation and cell's death. This fact about the two opposing signaling molecules leads us to investigate the effects of all ceramide related metabolites using metabolic control analysis and metabolic pathway analysis.
Drug target identification by metabolic control analysis
The discovery of the key enzymes functioning in the sphingolipid metabolism is essential for both understanding the metabolism and identifying drug targets for cancer therapy. The control coefficients belonging to the metabolic system given in Table 1 are used to identify the critically important enzymes that can be used as potential drug targets in future applications. A high concentration control coefficient (CCC) indicates that a change in the enzyme concentration is strongly reflected in the desired metabolite concentration. For analyzing and processing the CCCs, the set of metabolites is grouped into two parts as they lead to different cellular processes. The 'tumor suppressor' lipids (DHS, PHS, DHCer, PHCer, complex sphingolipids) are examined in a different category than the ''tumor-promoting' lipids of DHS-P and PHS-P. The enzymes that catalyze the reactions containing this set of metabolites and the related fluxes and also have high control coefficients are selected as a good starting point in drug target identification. The ultimate drug designed to target the enzyme with high or optimum control coefficient is expected to have an efficient outcome that can be achieved by a small concentration introduced to the organism.
Selection algorithms (SA)
Using the first selection algorithm, the following enzymes are identified as candidates for being potential drug targets (Fig. 3) : palmitoyl-coenzyme A synthase (r 1 ), glycerol-3-phosphate acyltransferase (r 2 ), inositol-1-phosphate synthase (r 6 ), phosphoserine-phosphatase (r 9 ), acyl-coenzyme A binding protein (r 12 ), serine hydroxymethyl transferase (r 10 ), serine palmitoyltransferase (r 11 ), acetyl-coenzyme A synthetase (r 34 ), phosphatidate phosphatase (r 3 ), phosphatidylserine decarboxylase (r 16 ), phosphoinositol kinase (r 7 ), 4-hydroxylase (r 21 ), CDP-diacylglycerol synthase (r 4 ), phosphatidylinositol synthase (r 5 ), in the order of importance [The enzyme names are taken from [19] .]. By examining Fig. 3 , it can be seen that the critically significant candidate enzymes for being potential drug targets coincide for both concentration and flux control coefficients. Although the analysis of relative concentration control coefficient (CCC) scores indicates that the enzymes glycosylphosphatidylinositol (GPI) remodelase and IPC synthase catalyzing the 27th and 30th reactions can also be considered as significant, the relative flux control coefficient (FCC) scores of the reactions 27 and 30 are less than 0.5, namely 0.467 and 0.433, respectively. An FCC of 0.433 means that a change in the concentration of IPC synthase (rxn 30) affects 13 out of 30 reaction fluxes.
In the second algorithm the use of local thresholds caused the limit of enzyme selection to increase from 0.4 to 0.8, meaning that the enzymes manipulating more than 80% of 12 critical metabolites and 30 reactions are identified as candidates of drug targets. The concentration and flux control coefficients again point out to the same candidate enzymes (Fig. 4) . The candidate set includes the enzymes of the reactions 1, 2, 3, 6, 9, 10, 11, 12, 16 and 34. The second algorithm gives a more refined set of enzymes as expected.
The important reactions (r 1 , r 2 , r 9 and r 34 ) obtained from the third algorithm with 'average relative' weights of control coefficients compose a small subset of the previously identified reaction sets (Fig. 5) . These four reactions are related to the production and consumption of the fatty and amino acids required for the initiation of sphingolipid synthesis in S. cerevisiae. 
Apoptosis specific analysis
In apoptosis specific analysis (3rd algorithm), the constructed critical metabolite set is partitioned into two parts according to the knowledge about the action of metabolites on apoptosis in mammalian cells. The CCCs of the phosphorylated forms of the long chain bases are examined separately from that of the DHCer and PHCer utilizing the matrix of 'relative' weights of the control coefficients. Consequently, the enzymes catalyzing the reactions 1, 2, 6, 9, 11, 12, 21, 27 and 34 are selected as candidates for being drug targets (Table 4 and Fig. 6 ).
When the signs of the control coefficients are also taken into account instead of the absolute values, the activities of the enzymes belonging to the reactions 6, 9, 11 and 12 have to be decreased to obtain a decrease in the concentrations of DHS-P and PHS-P. The increase in the activities of the enzymes catalyzing the reactions 1, 2, 21 and 34 are found to cause negative influences on the concentrations of phosphorylated sphingoid bases of S. cerevisiae.
When the signs of flux control coefficients and their effects on ceramides are considered it can be seen that the enzymatic activity of reaction 34 should be increased in order to have an increase in the concentrations of both ceramides (DHCer and PHCer) in S. cerevisiae, whereas the enzyme activity of reaction 27 should be decreased to obtain a similar effect on ceramide concentration. Moreover, the enzymes catalyzing the reactions 6, 9, and 12 have negative effects and those catalyzing the reactions 1 and 2 have positive effects on DHCer but they have almost no influence on the concentration of PHCer.
Perturbations on candidate enzymes
Metabolic control analysis indicates that in order to be utilized in a cancer therapy approach (increasing ceramide concentration and decreasing phosphorylated long chain base concentrations), the activities of the enzymes catalyzing reactions 1, 2, 21 and 34 should be increased while the enzymatic activities belonging to reactions 6, 9, 11, 12, and 27 should be reduced.
The effects of these enzymes were studied at a 15% perturbation in their activities. The change in enzyme activities is kept low as it is required that the ultimate goal (i.e. ceramide accumulation) should be attained by a minimum disruption of the rest of the sphingolipid metabolism. The simulation results were examined using the relative changes in the DHCer, PHCer, DHS-P and PHS-P concentrations with respect to the wild type concentrations at the 24th hour of perturbation (Table 5) .
More than 50% increases with respect to the wild type are reached in DHCer concentrations (except for the enzymes catalyzing reactions 21, 27 and 34) ( Table 5 ). The most effective potential drug target enzyme for DHCer is glycerol-3-phosphate acyltransferase (r 2 ) with a 92.23% increase. The most effective enzyme that can be utilized as a candidate drug target for PHCer accumulation is the enzyme catalyzing reaction 27 with a 37.95% increase in the metabolite concentration. When the changes attained with the same enzymatic manipulations (15% increase/decrease) are compared for the two ceramides, it can be seen that DHCer is almost all the times more vulnerable to perturbations whereas PHCer is more robust. This result may indicate the biological significance of PHCer in S. cerevisiae cells. The critically important components of metabolic networks should be robust to alterations [39] .
Palmitoyl-coenzyme A synthase (r 1 ), glycerol-3-phosphate acyltransferase (r 2 ), phosphoserine-phosphatase (r 9 ) and acyl-coen- Table 4 Relative weights of concentration control coefficients of potential drug target enzymes identified by apoptosis specific analysis. Fig. 6 . The relative weights of concentration control coefficients of phosphorylated forms of long chain bases, dihydroceramide and phytoceramide for the selected enzymes.
The enzymes catalyzing the reactions 1, 2, 6, 9, 11, 12, 21, 27 and 34 are selected as candidates for being drug targets in apoptosis specific analysis.
zyme A binding protein (r 12 ) contribute to the decline in the concentration of DHS-P. When PHS-P is considered a 15% increase in the activity of glycerol-3-phosphate acyltransferase (r 2 ) is found to produce an 88% decrease in PHS-P concentrations after 24 h from the perturbation ( Table 5) . As it can be seen from Table 5 , the manipulation of the selected enzyme activities gives the desired end results, i.e. increase in DHCer and PHCer concentrations and decrease in DHS-P and PHS-P concentrations as required for the application of the novel cancer therapy approach.
Drug target identification by metabolic pathway analysis
Metabolic pathway analysis was performed for the improved system of reactions which are shown in Fig. 2 . The newly developed metabolic pathway was constructed in such a way that the very first substrates and the end products are consistent with the system employed in the metabolic control analysis. Since the metabolic pathway analysis is a stoichiometric tool the reactions in the improved model are stoichiometrically balanced including the cofactors and hydrogen, and the lumped reactions are decomposed. The current sphingolipid pathway used in metabolic pathway analysis has 54 reactions and 41 transport reactions and 67 metabolites.
Elementary flux modes (EFMs)
Elementary flux modes are here used to identify the functionally and structurally important enzymatic steps in the S. cerevisiae sphingolipid metabolism and hence degree of control of reactions. The present system of sphingolipid reactions resulted in 2446 elementary flux modes which were studied in terms of two different approaches, i.e. common reactions among selected EFMs and control effective fluxes.
The key metabolites, DHCer, PHCer, DHS-P and PHS-P, are found to participate in 164 out of 2446 calculated EFMs. The common reactions available in all the 164 EFMs were reactions 1, 2, 9, 11, 13, 15, 20, 23, 26, 32 and 33 . Furthermore the transport reactions of adenosine triphosphate (ATP), 3-phosphoserine (3PS), glycerol-3-phosphate (G3P), cytidine triphosphate (CTP), reduced nicotinamide adenosine dinucleotide phosphate (NADPH), oxygen (O 2 ), adenosine monophosphate (AMP), diphosphate (DP), phosphate (P), cytidine monophosphate (CMP), carbon dioxide (CO 2 ), nicotinamide adenosine dinucleotide phosphate (NADP) and phosphatidyl ethanolamine (PE) were also identified as common reactions occurring in all the selected EFMs of the key metabolites set.
In an additional EFM analysis, a second set of critical metabolites were constructed where the end products of the sphingolipid pathway that is the complex sphingolipids, IPC, MIPC and M(IP) 2 C synthesized from both DHCer and PHCer were also taken into con- Table 5 The perturbation studies on candidate enzymes. The effect of 15% perturbations in candidate enzymes on key metabolite concentrations at the 24th hour of the simulations. The most effective changes in each key metabolite are highlighted. sideration beside the elements of the first set. However, there were no EFMs in which all the constituent metabolites of the second set participated.
Control effective fluxes (CEFs)
The information for the identification of potential drug targets was extracted from the determined elementary flux modes via control effective flux (CEF) analysis. The calculated CEF values for the internal fluxes excluding the transport reactions are given in Table 6 using the first objective function set. The first 10 reactions were identified as candidates of potential drug target enzymes. The candidate enzymes catalyze the reactions 34, 35, 1, 9, 13, 2, 4, 5, 30 and 39 0 in the order of their importance. As a concluding remark that can be dictated from the metabolic pathway analysis results, the reactions 1, 2, 4, 5, 9, 11, 13, 15, 20, 23, 26, 30, 32, 33, 34, 35 and 39 0 may be stated to be potential drug targets (Table 7) . When the candidate enzymes proposed for being drug targets achieved by metabolic pathway analysis are put side by side with the known potential drug target enzymes in pre-clinical or clinical development stages of drug discovery, it can be seen that metabolic pathway analysis can identify the known targets such as the enzymes of reactions 11, 15, 20 and 23. The mathematical tools' efficiency for drug target identification performed in this study is thus validated by the clinically available drugs.
Discussion
We combined the results of the two mathematical tools (MCA and MPA) to obtain a more complete view and reached an ultimate set of potential drug target enzymes (Table 7) . These common enzymes that are indicated by both MCA and MPA results are of the reactions 1, 2, 9, 11 and 34 and they are identified by at least four out of five of the methods discussed here. Moreover, if the target enzymes that appear in at least one of the MCA selection algorithms and one of the MPA computations are also included in this final set, the enzymes catalyzing the reactions 4, 5 and 11 emerge to be the additional candidates. Besides these, the known drug target enzymes from the literature that are identified by the MPA results could also be included in the concluding set (r 11 , r 15 , r 20 , r 23 ). The target enzymes that are determined by all the three selection algorithms of MCA but not MPA, i.e. enzymes belonging to reactions 6 and 12, can be added to the candidate list due to their reliability by passing all selection criterions of MCA. Another reason for including reaction 6 in the ultimate set of potential drug targets is that the manipulation of the enzyme activity of reaction 6 does not disturb the complex sphingolipid concentrations much with the percent change values of À15.46%, 14.73% and À19.47% for the IPC, MIPC and M(IP) 2 C, respectively (Table 5 ). An ideal drug is expected not to affect the metabolism other than its targets.
Although not identified by MPA results, reactions 21 and 27 from MCA results are also taken into account due to reaction 27's essential effect on PHCer accumulation (37.95% change, Table 5 ) and reaction 21's almost null effect on complex sphingolipids. The manipulation of the enzyme activity of reaction 21 has its desired effects on ceramide accumulation and long chain base phosphate depletion but it does not change the complex sphingolipid content of the cell with respect to wild type, i.e. À22.42%, À18.56% and À8.85% alterations in IPC, MIPC and M(IP) 2 C's concentrations, respectively ( Table 5) .
The drug targets proposed in this study are found to be more conserved than the other enzymes in the sphingolipid network (Supplementary Table 1 ).
Biological meaning of the potential drug targets
The first reaction catalyzed by palmitoyl-coenzyme A synthase, supplies the system with the fatty acid, Pal-CoA, which is needed for the very first step of de novo sphingolipid synthesis, i.e. condensation of Pal-CoA and serine in the endoplasmic reticulum to yield 3-ketodihydrosphingosine. The significance of the glycerol-3-phosphate acyltransferase enzyme catalyzing the second reaction comes from the fact that the second reaction is a branch point for the consumption of Pal-CoA. Pal-CoA can enter the de novo sphingolipid synthesis via reaction 11 or it can shift to the fatty acid metabolism via reaction 2. This enzyme is on the path of supplying substrates to the sphingolipid metabolism. The cell decides to enhance the production of either sphingolipids or fatty acids at this branch point. Cytidine diphosphate-diacylglycerol (CDP-DAG) synthase (r 4 ) and phosphatidylinositol synthase (r 5 ) have roles in the phospholipids pathway and they serve as the source of PI required for the synthesis of complex sphingolipids. Their importance relies on the fact that they function on the path of complex sphingolipid synthesis. 4-Hydroxylase (r 21 ) is also proposed to be a potential drug target according to the results of metabolic control analysis; this reaction yields the conversion of DHS to PHS. In some literature resources [5, 6, 16, 40] , it is reported that DHCer is not biologically active in mammalian cells, whereas the same remark cannot be stated for S. cerevisiae at least with the experimental evidence available currently [41] [42] [43] reporting the biological function of DHCer in apoptosis in human cancer cells. The significance of the conversion of DHS to PHS in S. cerevisiae may emphasize a more active role to PHS when compared with DHS just as in mammalian cells. Acetyl-coenzyme A synthetase is the enzyme catalyzing the 34th reaction, functioning in the fatty acid synthesis. The precursor fatty acid that is necessary for the production of the initiator fatty acid Pal-CoA of the sphingolipid pathway is produced by reaction 34. The significance and controlling effect of the enzyme is due to this reason. Table 7 Potential drug targets that are determined using five different computational tools. Three selection algorithms are employed for the examination of metabolic control analysis; using global threshold (MCA S.C. 1), local threshold (MCA S.C. 2) and apoptosis specific analysis (MCA S.C. 3). Two different computations are performed in metabolic pathway analysis; calculation of elementary flux modes (MPA EFM) and control effective flux values (MPA CEF). The enzymes that are known drug targets in clinical development stages are also indicated as bold. Inositol-1-phosphate synthase functions as the catalyst of reaction 6 that supplies inositol to the sphingolipid metabolism. In the model system under investigation, reaction 6 is the only source for inositol and it was classified as a critically important enzymatic step. Inositol is essential for the synthesis of complex sphingolipids because it is the precursor metabolite of phosphatidyl inositol. Phosphoserine-phosphatase functions as the supplier of serine (r 9 ) is necessitated for the beginning of de novo sphingolipid production. Serine palmitoyltransferase enzyme catalyzing reaction 11 is one of the drug targets described in the literature [7, 9] , drugs targeting this enzyme are now at pre-clinical or clinical development stages. This step is also identified in this study as one of the significant control points that can be used in cancer therapy. The importance of this enzymatic step comes from the fact that it is the initial reaction of the de novo sphingolipid synthesis. Twelfth and 27th reactions are two exchange reactions which deplete the essential fatty acid needed for the initiation of de novo sphingolipid synthesis: Pal-CoA and PHCer, respectively. Since these reactions are the direct consumers of the two essential metabolites of sphingolipid metabolism, the two exchange reactions are specified and proposed to be candidates for being potential drug targets. Acyl-coenzyme A binding protein is responsible for the exchange of Pal-CoA in reaction 12 and it is the GPI remodelase enzyme that executes reaction 27. Reactions 15 and 20 are catalyzed by sphingolipid long chain base kinase and responsible for the formation of DHS-P and PHS-P, respectively. These reactions are the ones that directly produce the phosphorylated forms of the long chain bases.
Conclusion
When the two systems biology tools employed in the current study are compared in terms of their potency in potential drug target identification, it can be seen that metabolic pathway analysis results overlap more with the known drug targets in the literature. Metabolic control analysis results, on the other hand, are more informative since one can gather information about the direction of action, i.e. whether one should inhibit or activate the target enzyme. Thus, MCA results go one step further on the way to drug discovery and drug design.
In conclusion, the enzymes catalyzing the reactions 1, 2, 4, 5, 6, 9, 11, 12, 15, 20, 21, 23, 27 and 34 are proposed as putative drug targets by both MCA and MPA. The activities of palmitoylcoenzyme A synthase (r 1 ), glycerol-3-phosphate acyltransferase (r 2 ), CDP-DAG synthase (r 4 ), phosphatidylinositol synthase (r 5 ), 4-hydroxylase (r 21 ), ceramide synthase (r 23 ) and acetyl-coenzyme A synthetase (r 34 ) should be increased to obtain the ceramide accumulation and long chain base phosphate depletion and the activities of inositol-1-phosphate synthase (r 6 ), phosphoserinephosphatase (r 9 ), serine palmitoyl transferase (r 11 ), acyl-coenyzme A binding protein (r 12 ), sphingolipid long chain base kinase (r 15 and r 20 ) and GPI remodelase (r 27 ) should be decreased in order to reach the same cancer therapy essentials. Integration of the results of the two theoretical frameworks as we have done in this study can be utilized in future in other drug target identification studies.
In order to obtain more efficient drugs in cancer therapy; drugs targeting two or more enzymes may be developed or two or more drugs may be utilized at the same time course. There is clinical evidence of using drugs [7, 9] both inhibiting ceramide catabolism and generating ceramide simultaneously.
